EpiVax

Biotechnology · Vaccines
$425klatest round · Venture round · Aug 2020 · 6 yr ago
$1.5Mgrants · 4 grants · CORDIS
50+team · employees, estimated range
2017founded

Overview

EpiVax leads the industry in immunogenicity assessment and sequence optimization for biologic therapeutics and vaccines. Utilizing proprietar.

Funding and backers

Total raised
$425k
5 rounds on record
Latest round
$425k
Venture round · Aug 2020 · 6 yr ago
Team
51-200
employees, estimated range
Grants
$1.5M
4 grants · CORDIS
The money's age
Long since its last round
74 months since the last round · not hiring
Momentum
0/100
no fresh signals
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Aug 1, 2023 Won a grant $300k · CORDIS Aug 7, 2020 Raised a round Venture round $425k · SEC Form D May 9, 2018 Won a grant $325k · CORDIS Sep 1, 2017 Won a grant $317k · CORDIS 2017 Founded Jul 1, 2016 Won a grant $591k · CORDIS
Funding rounds
RoundDateAmountInvestorsSource
Grant Aug 2023 $300k — CORDIS
Venture round Aug 2020 $425k — SEC Form D
Grant May 2018 $325k — CORDIS
Grant Sep 2017 $317k — CORDIS
Grant Jul 2016 $591k — CORDIS
Registers and programsofficial lists and records that name the company
Legal entity EpiVax Therapeutics, Inc. SEC Form D
Founders and leadersfrom filings, registers and the company's site
Clifford GrimmExecutive OfficerSEC Form D
Anne De GrootExecutive Officer, DirectorSEC Form D
William MartinExecutive Officer, DirectorSEC Form D
Investors in similar startupsfunds that back the companies most like this one
Techstars
backs CowTribe
SFC Capital
backs ReNewVax logo
RA Capital Management
backs GIVAX
IQ Capital
backs Base Immune
42CAP
backs 2026 Alp Bio AG
Hoxton Ventures
backs Base Immune
Similar startupsby what they do, their industry and backers
Deep FlareFounded 2020
Deepflare predicts true T-cell immunogenicity with 12x greater accuracy than standard tools. Design next-generation antigen candidates for…
Hexamer TherapeuticsVenture round $500k · 4 mo ago · 1-10 employees
Innovators in natural vaccine technology. Explore rapidly engineered, scalable vaccine technologies at Hexamer Therapeutics.
Primrose BioVenture round $15M · 2 yr ago · Founded 2023 · 51-200 employees
Primrose Bio develops and commercializes manufacturing technologies that close gaps in biologics, mRNA and vaccine production.
2026 Alp Bio AG
Immunogenicity intelligence, grounded in human biology.. — Problem.
ReNewVax logoVenture round · 10 mo ago · Founded 2022
Protecting Our Future. ReNewVax is a next-generation bacterial vaccine company developing the first universal vaccine targeting all ca.100…
Base ImmuneVenture round · 13 mo ago · Founded 2019 · 11-50 employees
404 Err….or The vaccines you're looking for don't exist. Yet….

Visa sponsorship

United StatesUS 0
0
H-1B filings in 12 months
0
Open roles in United States
In the register as EpiVax, Inc., Providence, RI
Other sponsors in the same field
Terrestrial 4 filingsVersatope Therapeutics 2 filingsCalder BiosciencesModerna 101 filings
Alert me
US Department of Labor · latest filing Jun 17, 2025 · Visa details by country

Financials

Total raised
$2M
Latest round
Grant
Funding rounds
5
Funding rounds
Round Announced Amount
Grant 2023 $300k Details
Venture - Series Unknown 2020 $425k Details
Grant 2018 $325k Details
Grant 2017 $317k Details
Grant 2016 $591k Details

People

Clifford Grimm
Executive Officer
SEC Form D
Anne De Groot
Executive Officer, Director
SEC Form D
William Martin
Executive Officer, Director
SEC Form D
Richard Lipkin
Director
SEC Form D
Daniel Adams
Director
SEC Form D
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data

Offices

Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
Providence United States
HQ
Corporate Office/Laboratory:
50-200 est. staff
188 Valley Street, Suite 424, Providence, RI 02909, USA
company site